VOR Protein Complex Inhibition to Block Intercellular Disease Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer and viral diseases, such as HIV, face challenges including drug resistance, inadequate targeting of affected cells, and ineffective disruption of intercellular communication pathways mediated by the tripartite VAP-A, ORP3, and Rab7 (VOR) protein complex, which facilitates the transport of disease-causing materials into healthy cells.
Innovation Solution
Inhibition of the tripartite VAP-A, ORP3, and Rab7 protein complex in multicellular organisms through chemical or biological agents, disrupting intercellular communication and viral infection mechanisms, thereby preventing the transport of endocytosed biomaterials to the nucleus of recipient cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy or antiretroviral therapy is used to treat cancer and viral diseases, then initial treatment effectiveness is achieved, but drug resistance develops and treatment effectiveness declines
Solution Approach 1:
The patent extracts and targets a specific molecular mechanism (the VOR protein complex) that is essential for disease progression but not directly involved in drug resistance development. By isolating and inhibiting this specific complex rather than using broad-spectrum chemotherapeutic agents, the treatment avoids the development of resistance while maintaining effectiveness against both cancer and viral diseases.
Solution Approach 2:
The VOR protein complex inhibitor demonstrates multi-functionality by effectively treating both cancer and viral diseases through a single mechanism of action. This universal approach addresses multiple disease types simultaneously, overcoming the limitation of disease-specific treatments that individually lose effectiveness over time.
2Object-affected harmful factors
If tumors are treated with conventional cytotoxic drugs and radiation, then initial tumor control is achieved, but tumors become more aggressive and develop resistance
Solution Approach 1:
The VOR protein complex acts as an intermediary mechanism that facilitates tumor progression and viral infection. By targeting this intermediary complex rather than directly attacking tumor cells or viral particles, the treatment disrupts the communication and transport pathways that tumors use to adapt and become more aggressive, thereby controlling tumor growth without selecting for resistant, aggressive variants.
3Reliability
If immunotherapeutic strategies are employed to combat cancer and viral infections, then immune response is enhanced, but challenges arise in defining target cell composition and maintaining stability
Solution Approach 1:
The patent shifts the therapeutic parameter from targeting immune cells or viral proteins (which require complex identification and stability management) to targeting the VOR protein complex's functional state. By changing the therapeutic parameter to a conserved molecular complex with defined composition and function, the treatment simplifies target identification while maintaining reliable effectiveness against both cancer and viral diseases.
Data Source
AI summary
The present disclosure relates generally to methods of inhibiting a tripartite VAP-A, ORP3 and Rab7 (VOR) protein complex in multicellular organisms, to methods of identifying agents which inhibit such complex and to the medical use of those agents. Inhibition of the VOR complex causes interference with at least one mechanism of intercellular communication, wherein the intercellular communication is mediated by receptor-ligand interaction and/or EVs, and viral infection involving the transport of endocytosed biomaterials to the nucleus of recipient cells.